PharmaEngine, Inc. operates as a biopharmaceutical company. The Company focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases.

Onivyde With Oxaliplatin, Fluorouracil And
Leucovorin Will Be Included In Taiwan Nhi For First-Line
Treatment Of Metastatic Pancreatic Adenocarcinoma

Pharmaengine Announces Board Resolution Of
Approval For 3q25 Financial Report

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmaengine Inc (4162 TT)

Onivyde With Oxaliplatin, Fluorouracil And Leucovorin Will Be Included In Taiwan Nhi For First-Line Treatment Of Metastatic Pancreatic Adenocarcinoma

Pharmaengine Announces Board Resolution Of Approval For 3q25 Financial Report

Pharmaengine Inc. To Attend Yuanta Securities Investors’Conference Hosted By Yuanta Securities

Announcement For The Board Of Directors Meeting Date Of The Third-Quarter 2025 Financial Report

Pharmaengine Announces First Patient Dosed In Phase I Trial Of Pep08 For Solid Tumor Cancers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)